Organoids as a predictive model for assessing chemotherapy treatment response in pancreatic cancer:single center study
10.3760/cma.j.cn113855-20250313-00144
- VernacularTitle:类器官模型应用于胰腺癌化疗敏感性预测的单中心研究
- Author:
Aohui YAN
1
;
Yongsu MA
1
;
Xiaodong TIAN
1
;
Yinmo YANG
1
Author Information
1. 北京大学第一医院肝胆胰外科，北京 100034
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Organoids;
Chemotherapy;
Drug sensitivity
- From:
Chinese Journal of General Surgery
2025;40(5):375-380
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To construct a patient-derived organoid model and clarify its predictive value for the sensitivity of pancreatic cancer chemotherapy drugs.Methods:A total of 42 tissue samples from patients with pancreatic ductal adenocarcinoma who underwent surgery or percutaneous biopsy at Peking University First Hospital from 2020 to 2023 were collected. Pancreatic cancer organoid models were constructed through in vitro culture. These organoid models were treated with five most commonly used pancreatic cancer chemotherapy drugs, namely Gemcitabine, nab-Paclitaxel, 5-Fluorouracil, Oxaliplatin, and Irinotecan, to determine the IC 50. The consistency between the organoid drug sensitivity test results and the patients' chemotherapy sensitivity was determined. Results:Patient-derived pancreatic cancer organoid models achieved an establishment success rate of 73.33%. The organoid model could reproduce the pathological features of the patients' tumor tissues; there were individual differences in the sensitivity to the same chemotherapy drug among organoid models derived from different patients. The sensitivity of patient derived organoids was highly consistent with the actual treatment effect of the corresponding patients was 81%.Conclusion:The drug susceptibility test results were significantly correlated with the actual medication response of patients, suggesting that the drug susceptibility test technology based on patient derived organoids has the potential to guide individualized chemotherapy for pancreatic cancer.
